Clinical Holds for Cell and Gene Therapy Trials: Risks, Impact, and Lessons Learned […]
Read More… from Molecular Therapy: Methods & Clinical Development – Review
Clinical Holds for Cell and Gene Therapy Trials: Risks, Impact, and Lessons Learned […]
Read More… from Molecular Therapy: Methods & Clinical Development – Review
GUMM: A Purpose-Built Computational Workflow for Single Cell Genotyping of Gene Editing Experiments […]
Development of a Gene Edited Next-Generation Hematopoietic Cell Transplant to Enable Acute Myeloid Leukemia Treatment by Solving Off-Tumor Toxicity […]
Read More… from Molecular Therapy: Methods & Clinical Development – Peer-Reviewed Manuscript
A Single Cell DNA Sequencing Resource and Computational Approach to Quantify CRISPR-Cas9 Gene Editing Allelism […]
Read More… from Cold Spring Harbor Lab Meeting – 2023 – Poster Presentation P203
CD33-Deleted Hematopoietic Stem and Progenitor Cells Display Normal Engraftment after Hematopoietic Cell Transplant (HCT) and Tolerate Post-HCT GemtuzumabOzogamicin(GO) Without Cytopenias […]
Gene Editing and Immunotherapeutic Targeting of ADGRE2/EMR2 to Enable Combinatorial Targeting in Acute Myeloid Leukemia (AML) […]
Initial First-In-Human Results: CD33-Deleted Hematopoietic Stem and Progenitor Cells Display Normal Engraftment after Hematopoietic Cell Transplantation (HCT) and Tolerate Post-HCT Gemtuzumab Ozogamicin (GO) without Cytopenias […]
Read More… from EBMT Annual Meeting – 2023 – Poster Presentation P249
Translocation Detection and Quantification Workflow to Characterize CRISPR-Cas Multiplex Edited Hematopoietic Stem and Progenitor Cells (HSPCs) […]
Read More… from Keystone Symposia – 2023 – Poster Presentation 3527
Initial First-In-Human Results: CD33-Deleted Hematopoietic Stem and Progenitor Cells Display Normal Engraftment after Hematopoietic Cell Transplant (HCT) and Tolerate Post-HCT Gemtuzumab Ozogamicin (GO) without Cytopenias […]
Read More… from Tandem Meetings – 2023 – Poster Presentation LBA14